ArticleBMC nephrology2025
Comparison and prognostic analysis of focal segmental glomerulosclerosis patients with or without nephrotic syndrome at onset.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundFocal segmental glomerulosclerosis (FSGS) constituted one of the most common causes of end-stage kidney disease. We aimed to compare the presentation and prognosis for FSGS patients based on whether they met the criteria of nephrotic syndrome (NS) at disease onset.
methodsRetrospective analysis of 291 treatment-naïve adult FSGS patients managed per clinical guidelines. Patients were categorized into non-NS-FSGS (n = 158) and NS-FSGS (n = 133) groups based on NS criteria. Immunosuppressants were administered based on KDIGO 2021 Guideline and disease progression. Kidney outcomes were analyzed in 144 patients followed up for more than 1 year.
resultsA total of 291 FSGS patients were included, with 158 patients in the non-NS-FSGS group and 133 patients in NS-FSGS group. Patients in the non-NS-FSGS group exhibited higher prevalences of hypertension, along with higher body mass index, hemoglobin level, eGFR, serum albumin and immunoglobulin levels, and more severe chronic pathological changes compared to those in NS-FSGS group. Among patients followed up for more than 1 year, the annual eGFR decline rate (ADR) was 5.0 (2.4, 10.1) % in the non-NS-FSGS group and 2.1 (0.6, 6.1) % in NS-FSGS group (P = 0.922); ADR > 5% was more common in non-NS-FSGS patients than in NS-FSGS patients (49.3% vs. 29.0%, P = 0.017), especially than treatment-responsive patients in the NS-FSGS group (49.3% vs. 17.2%, P < 0.001). For the non-NS-FSGS group, multivariate Cox regression revealed that persistent urinary protein-creatinine ratio (uPCR) ≥ 0.5 during follow-up (HR 2.455, 95% CI 1.105-5.454, P = 0.027) was an independent risk factor for ADR > 5%.
conclusionsFSGS patients without NS at onset experienced a faster decline in kidney function compared to those with NS, particularly those with treatment-responsive NS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.